A Phase I-II Trial Of MK-0646 A Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor In Combination With Etoposide And Cisplatin in Extensive Stage Small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Dalotuzumab (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jul 2012 Actual patient number is 12 according to ClinicalTrials.gov.
- 06 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.